Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of nivolumab (ONO-4538) in advanced non-squamous NSCLC after platinum therapy
jRCT2080222027Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Non-small cell lung cancer (NS-NSCLC) and bronchial carcinoma, sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate (ORR). Started Feb 2013; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on jRCT2080222027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222027.